Effect of topical glucocorticoid treatment in chinchilla model of lipopolysaccharide induced otitis media with effusion.
OBJECTIVE
To compare the efficacy of topical treatment with three glucocorticoids in lipopolysaccharide induced otitis media with effusion (OME).


METHODS
Chinchillas were divided into seven treatment groups consisting of vehicle and three glucocorticoids: dexamethasone sodium phosphate (DSP), fluticasone propionate (FP), and hydrocortisone, each at concentrations of 0.1% and 1.0%. LPS (300 μg) was injected into the superior bullae of chinchillas to induce OME. Animals were treated with test substances at -2, 24, and 48 h relative to LPS inoculation. After 96 h, chinchillas were euthanized, samples of middle ear effusion (MEE) were collected, and temporal bones were removed for histopathological examination. Reduction of OME was evaluated by measuring MEE volume and thickness of mucosal lining for each bulla.


RESULTS
One percent treatment of FP significantly reduced MEE. One percent treatment of DSP and HC significantly reduced the mucosal thickness (MT), DSP (15.0 μM) more than HC (30.8 μM). Treatment with 0.1% glucocorticoids did not lead to any significant reduction.


CONCLUSIONS
Clearance of otitis media with effusion seems to be a class effect among glucocorticoids. DSP was the best in reducing MT. It is important to evaluate treatment with various glucocorticoids in order to discover alternative drugs for OME.
Pudrith
Charles
C
Department of Otolaryngology-Head & Neck Surgery, Loma Linda University School of Medicine, Jerry L. Pettis Memorial Veterans Affairs Medical Center, USA.
Kim
You Hyun
YH
Martin
Dusan
D
Gupta
Amar
A
Inman
Jared
J
Wareham
Rachelle
R
Jahng
Patrick
P
Chung
You Sun
YS
Wall
G Michael
GM
Jung
Timothy
T
D000287:Administration, Topical; D000730:Androstadienes / Q000008:administration & dosage*; D000818:Animals; D002682:Chinchilla; D003907:Dexamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004195:Disease Models, Animal; D005260:Female; D000068298:Fluticasone; D005938:Glucocorticoids / Q000008:administration & dosage*; D006854:Hydrocortisone / Q000008:administration & dosage*; D008070:Lipopolysaccharides / Q000009:adverse effects; D008297:Male; D009092:Mucous Membrane / Q000473:pathology; D010034:Otitis Media with Effusion / Q000188:drug therapy* / Q000209:etiology; D013701:Temporal Bone / Q000473:pathology
D000730:Androstadienes; D005938:Glucocorticoids; D008070:Lipopolysaccharides; C004180:dexamethasone 21-phosphate; D003907:Dexamethasone; D000068298:Fluticasone; D006854:Hydrocortisone